{"id":633731,"date":"2025-10-02T10:10:56","date_gmt":"2025-10-02T14:10:56","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=633731"},"modified":"2026-01-28T14:07:06","modified_gmt":"2026-01-28T19:07:06","slug":"zepbound-generic","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/zepbound-generic\/","title":{"rendered":"Zepbound generic: Availability, cost, and weight loss alternatives"},"content":{"rendered":"

Zepbound<\/span><\/a> (tirzepatide) is a weekly injectable medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of long-term weight management and obstructive sleep apnea (OSA) in combination with a diet and exercise regimen. As of now, there\u2019s no generic for Zepbound, but one will likely be made once the drug\u2019s patent expires, which is estimated to be 2036 or later.<\/span><\/p>\n

Is there a generic for Zepbound?<\/span><\/h2>\n

Zepbound is a dual GLP-1 and GIP receptor agonist that helps reduce appetite, slow digestion, and improve the body’s processing of fat and sugar. The injectable medicine, sold and patented by Eli Lilly and Company, contains the active ingredient tirzepatide, which was first approved under the brand name Mounjaro in May 2022 to improve glycemic control in people with Type 2 diabetes. Tirzepatide was later approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight, who have at least one weight-related condition (e.g., high blood pressure, Type 2 diabetes, or high cholesterol), in addition to diet and exercise. In December 2024, Zepbound was approved for adults with OSA, making it the first prescription medication for certain people with the sleep disorder.\u00a0<\/span><\/p>\n

Rekha Kumar, MD, MS, an endocrinologist and obesity medicine specialist, as well as Medical Advisor at Found in New York City, states that there is currently no Zepbound generic available. \u201cThat\u2019s pretty typical with newer medications as the company that developed it holds a patent, which means they have a period of time before generics can come to market,\u201d she explains. \u201cIt usually takes years before we see generic versions of breakthrough drugs like this one.\u201d<\/span><\/p>\n

Eli Lilly Company\u2019s four U.S. patents for the active ingredient in Zepbound, tirzepatide, are set to expire on May 13th, 2026, which is when they\u2019ll be open to patent challenges. Based on estimates, the launch of the Zepbound generic is not expected to be available until June 2039.\u00a0<\/span><\/p>\n

While there\u2019s no generic Zepbound available yet, here are some insights into the injectable medication, including uses, dosages, side effects, and more:<\/span><\/p>\n\n\n\n\n\n\n\n\n
<\/td>\nZepbound<\/span><\/td>\n<\/tr>\n
Uses<\/span><\/td>\n\n
    \n
  • Chronic weight management for people who are obese or overweight with one or more of the following conditions:<\/span>\n
      \n
    • Obstructive sleep apnea (OSA)<\/span><\/li>\n
    • High blood pressure (hypertension)<\/span><\/li>\n
    • Type 2 diabetes<\/span><\/li>\n
    • High cholesterol (dyslipidemia)<\/span><\/li>\n<\/ul>\n<\/li>\n
    • Moderate to severe obstructive sleep apnea in adults with obesity<\/span><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
Standard dosage<\/span><\/td>\n\n
    \n
  • Initially, 2.5 milligrams (mg) once weekly for four weeks<\/span><\/li>\n
  • Dosages can increase to 5 mg, 10 mg, or 15 mg once weekly<\/span><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
Common side effects<\/span><\/td>\n\n
    \n
  • Nausea<\/span><\/li>\n
  • Vomiting<\/span><\/li>\n
  • Diarrhea<\/span><\/li>\n
  • Constipation<\/span><\/li>\n
  • Stomach pain<\/span><\/li>\n
  • Burping<\/span><\/li>\n
  • Heartburn<\/span><\/li>\n
  • Indigestion<\/span><\/li>\n
  • Tiredness<\/span><\/li>\n
  • Dizziness<\/span><\/li>\n
  • <\/li>\n
  • <\/li>\n
  • Hair loss\u00a0<\/span><\/li>\n
  • Injection site reactions<\/span><\/li>\n
  • Allergic reactions<\/span><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
Contraindications<\/span><\/td>\n\n
    \n
  • Hypersensitivity (severe allergic reaction) to the drug, such as anaphylaxis or angioedema<\/span><\/li>\n
  • Personal or family history of medullary thyroid carcinoma (MTC)<\/span><\/li>\n
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)<\/span><\/li>\n
  • Caution in pregnancy and breastfeeding<\/span><\/li>\n
  • Caution in people with diabetic retinopathy (a type of diabetic eye disease)<\/span><\/li>\n
  • Caution in using oral contraceptives, such as birth control pills<\/span><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
Other considerations<\/span><\/td>\n\n